Biotech News

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

Rocket Pharmaceuticals (RCKT)ir.rocketpharma.com2026-06-12 11:06 ESTCommercial

CRANBURY, N.J. --(BUSINESS WIRE)--Jun. 12, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the closing of the sale of its

Open original release

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

Rocket Pharmaceuticals

Rocket Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

RCKTRocket Pharmaceuticals2026-05-08 00:13:05 EST

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

RCKTRocket Pharmaceuticals2026-05-06 19:25:44 EST

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RCKTRocket Pharmaceuticals2026-05-06 19:25:43 EST

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

RCKTRocket Pharmaceuticals2026-05-06 19:25:43 EST

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States